Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cryo-Cell International and EndGenitor Technologies have signed a new research collaboration to co-develop a combined cellular platform therapeutic for rapidly forming vasculature in injured tissues.
Subscribe to our email newsletter
The research will focus on the utilization of cord blood and menstrual blood derived cells, known as ECFCs and MenSCs, respectively. ECFCs are cord blood-derived endothelial colony-forming cells.
The ECFCs are currently in preclinical development by EndGenitor for cardiovascular and other therapeutic applications. MenSCs, which were discovered and developed by Cryo-Cell, are primitive mesenchymal progenitor cells found in menstrual blood and are easily retrievable without invasive techniques.
Julie Allickson, vice president of laboratory operations and R&D at Cryo-Cell, said: “We think the project has significant potential, as both ECFCs and MenSCs contribute to angiogenesis in vivo, which underscores the importance of further study into the potential synergy of these cells in the formation of vasculature.”